Lime Therapeutics

Lime Therapeutics is thrilled to continue expanding! Join one of New York City's most exciting and fastest growing drug discovery companies. If you're passionate about discovering cancer treatments and working with a first-class team, this is the role for you. Feel free to share this post with your network. Please note that we will not be working with external recruiters, and will not be able to respond to personal messages from candidates regarding this opening. #drugdiscovery #biotechstartup #limetherapeutics #newyorkcity #newyorkbio #cancerdrugdiscovery #jobopening #targetvalidation #translationaldrugdiscovery

Lime Therapeutics is back on the hiring trail! We are looking for a talented and driven Research Associate to join our fast-growing company. As an RA, you will have a direct impact on discovery of new cancer therapies, and our top-tier scientists will provide first-rate mentorship to guide your professional development. This in-person role is based at our beautiful headquarters in Biolabs@NYULangone, in the heart of NYC's SoHo neighborhood. Apply today, and please share this post! Thank you in advance for your understanding: -We will not respond to LinkedIn messages from candidates  -We will not be working with external recruiters for this role #hiring #biotechjobs #nycbiotech #cancer #drugdiscovery #limetherapeutics #researchassociate

It’s a pleasure to share our recent cover page article on ChemoGenics BioPharma.  I am thrilled to see Lerociclib, the best in class CDK4/6 compound for breast cancer finishing its Phase 3 trials. This would be the second compound going commercial that was discovered at ChemoGenics through our collaborative drug discovery efforts. It’s a blessing to have worked with so many clients who have entrusted their valuable research to ChemoGenics over the years, some of whom have become great personal friends. I look forward to continual collaborations with current and potential future clients to help them succeed in their research endeavors.

Lime Therapeutics is hiring! We are looking for an exceptionally talented PhD Scientist – Target Validation and Translational Drug Discovery. The ideal candidate will help us bring game-changing treatments to patients, by taking ownership of research programs and being a team player within our ambitious group. Are you the missing puzzle piece? If so, apply to join one of New York City's most exciting biotech companies! Please share this posting with anyone who might be interested. Note that we are not accepting external recruiters at this time.

Allow us to share with you the joy of our recent investment in Lime Therapeutics 🔬 – US-based biotech startup developing a game-changing drug discovery platform. Using an ultrasensitive lipid detection technology, the platform is able to target conditions such as cancer, metabolic disorders, and neurodegenerative diseases. Founded by a team with expertise in immunology, nanosensor technologies, and drug discovery, Lime Therapeutics has established relevant partnerships with pharmaceutical companies. 🤝 Huge congrats to the core team | Shardule Shah, PhD, MBA | Prakrit Jena | Daniel Heller | Mariluz Soula, PhD | on their progress up to date and looking forward to watching their future path 🚀 For more info see the link to a full article in comments. #investment #startup #biotech #lipidmetabolism #lipidbiology #lipiddysfunction #cancersucks #stopcancer #drugdiscovery

Kicking off 2024’s Industry Insights on Research and Innovation Seminar Series with a fantastic talk! We are very grateful to Dr. Shardule Shah, PhD, MBA and Dr. Prakrit Jena for coming to NYU and sharing Lime Therapeutics’ promising science and story. Our trainees, faculty, and clinicians particularly enjoyed hearing their tips and tricks for building a biotech. #IIRIS_series #research #innovation #science  #development #startups #biotech

Lime Therapeutics is proud to announce that we are starting a collaboration with the Novo Nordisk #BioInnovationHub through its Co-Creation Greenhouse Program. Through this collaboration, we will combine Novo Nordisk’s deep disease biology understanding with our expertise in real-time lipidomics. By leveraging our breakthrough lipid flux monitoring platform and data science capabilities, we will explore new therapeutic opportunities to improve efferocytosis in metabolic-dysfunction-associated steatohepatitis (MASH) and cardiometabolic disorders such as atherosclerosis. We look forward to working alongside Uli Stilz and Novo Nordisk’s Bio Innovation Hub team to apply our understanding of lipid monitoring while collaborating to uncover novel pharmacology that can potentially make a difference in the lives of people living with these conditions. #lipids #novonordisk #limetherapeutics #collaboration #cardiometabolism #atherosclerosis #mash #liverdisease